Ask VialBase
Research

A Study of Tirzepatide in Participants With Metabolic Dysfunction-Associated Steatotic Liver Disease With Alcohol Component (MetALD) — VialBase Research

Trial Summary

Phase 2 trial evaluating tirzepatide for MetALD, a newly defined category in the updated MASLD/MASH nomenclature that captures patients with metabolic liver disease who also have significant alcohol consumption. This is an underserved population often excluded from prior NASH trials.

Design

  • Type: Randomized, double-blind, placebo-controlled, dose-finding
  • Population: Adults with MetALD confirmed by imaging or biopsy
  • Arms: Multiple tirzepatide doses vs. placebo
  • Duration: 48-72 weeks anticipated
  • Key measures: Liver fat reduction (MRI-PDFF), liver histology, ALT normalization, metabolic parameters

Key Outcomes

Trial is recruiting; no results available yet.

Significance for Peptide Research

MetALD is a newly recognized clinical entity. This trial positions tirzepatide at the frontier of liver disease treatment, targeting a mixed-etiology population. The dual GIP/GLP-1 mechanism may offer advantages over GLP-1-only agents in hepatic fat metabolism. Success here would expand the incretin-based liver disease treatment landscape beyond traditional NASH boundaries.

See Also